Whitehawk Therapeutics, Inc. (WHWK) Income Statement
WHWK 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsWHWK revenue and net income
Where WHWK's revenue goes
2025Each bar shows an amount and its share of revenue. WHWK kept −288.3% of revenue as net income.
WHWK profit margins
WHWK growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −72.5% | −22.3% | −13.3% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
WHWK quarterly EPS vs estimates
Whitehawk Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.26).
WHWK income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $1.1M | $14.6M | $749,000 |
| Cost of revenue | $760,000 | $54.1M | $51.7M | $34.0M | $19.7M | $15.0M | $11.1M |
| Gross profit | $6.4M | −$28.1M | −$27.4M | −$18.8M | −$18.6M | −$428,000 | −$10.3M |
| Research & development | $91.0M | $51.0M | $48.9M | $32.7M | $19.7M | $15.0M | $11.1M |
| Sales, general & admin | $29.8M | $36.7M | $44.5M | $40.2M | $18.5M | $2.1M | $1.9M |
| Total operating expenses | $120.8M | $39.4M | $44.5M | $43.9M | $92.7M | $2.1M | $1.9M |
| Operating income | −$114.4M | −$67.5M | −$71.9M | −$62.7M | −$111.2M | −$2.5M | −$12.2M |
| Interest income | $6.2M | $3.9M | $6.4M | $2.4M | $13,000 | $41,000 | — |
| Interest expense | $0 | $154,000 | $231,000 | $230,000 | $665,000 | $815,000 | $83,935 |
| Income before taxes | −$20.6M | −$63.7M | −$65.8M | −$60.5M | −$110.1M | −$3.5M | −$12.3M |
| Income taxes | — | — | — | — | $2,000 | $2,000 | $1,300 |
| Net income | −$20.6M | −$63.7M | −$65.8M | −$60.5M | −$110.1M | −$3.5M | −$12.3M |
| EBITDA | −$20.5M | −$64.6M | −$65.4M | −$58.8M | −$37.0M | −$2.5M | −$12.2M |
| EPS (diluted) | −$1.71 | −$2.26 | −$2.44 | −$2.51 | −$3.63 | −$1.44 | −$8.60 |
| Gross margin | 89.4% | −108.0% | −112.4% | −123.4% | −1,656.2% | −2.9% | −1,377.2% |
| Operating margin | −1,601.1% | −259.6% | −295.4% | −411.9% | −9,930.1% | −17.5% | −1,624.8% |
| Net margin | −288.3% | −245.1% | −270.0% | −397.7% | −9,829.5% | −23.9% | −1,636.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $7.1M | $7.2M | $7.2M | $6.2M | $5.4M | $6.3M | $6.0M |
| Cost of revenue | $0 | $0 | $1,000 | $5,000 | $16,000 | $760,000 | $15.1M | $10.8M | $13.9M | $14.2M | $13.7M | $12.6M |
| Gross profit | $0 | $0 | −$1,000 | −$5,000 | −$16,000 | $6.4M | −$7.9M | −$3.6M | −$7.7M | −$8.9M | −$7.4M | −$6.6M |
| Research & development | $12.9M | $17.2M | $19.0M | $14.3M | $48.8M | $8.8M | $14.3M | $10.0M | $13.1M | $13.6M | $12.8M | $11.9M |
| Sales, general & admin | $5.2M | $6.3M | $5.9M | $5.2M | $5.9M | $12.8M | $11.1M | $7.2M | $7.9M | $10.6M | $10.3M | $11.2M |
| Total operating expenses | $18.1M | $23.5M | $24.9M | $19.5M | $54.7M | $21.6M | $11.1M | $9.8M | $7.9M | $10.6M | $10.3M | $11.2M |
| Operating income | −$18.1M | −$23.5M | −$24.9M | −$19.5M | −$54.7M | −$15.2M | −$18.9M | −$13.4M | −$15.6M | −$19.5M | −$17.7M | −$17.8M |
| Interest income | $1.5M | $1.3M | $1.6M | $1.9M | $2.0M | $791,000 | $676,000 | $906,000 | $1.1M | $1.3M | $1.5M | $1.6M |
| Interest expense | — | — | $0 | $0 | $0 | $0 | $0 | $38,000 | $58,000 | $58,000 | $57,000 | $58,000 |
| Income before taxes | −$16.6M | −$22.2M | −$23.3M | −$17.7M | −$52.6M | $73.0M | −$18.3M | −$12.5M | −$14.6M | −$18.3M | −$16.3M | −$16.3M |
| Net income | −$16.6M | −$22.2M | −$23.3M | −$17.7M | −$52.6M | $73.0M | −$18.3M | −$12.5M | −$14.6M | −$18.3M | −$16.3M | −$16.3M |
| EBITDA | −$18.1M | −$22.2M | −$23.2M | −$17.7M | −$52.6M | $73.1M | −$18.2M | −$10.7M | −$14.5M | −$18.2M | −$16.2M | −$16.2M |
| EPS (diluted) | −$0.20 | −$0.32 | −$0.34 | −$0.25 | −$0.76 | −$0.36 | −$0.67 | −$0.37 | −$0.54 | −$0.68 | −$0.60 | −$0.60 |
| Gross margin | — | — | — | — | — | 89.4% | −109.1% | −49.8% | −124.5% | −166.1% | −116.5% | −111.2% |
| Operating margin | — | — | — | — | — | −213.0% | −261.8% | −186.0% | −252.2% | −364.5% | −280.0% | −299.5% |
| Net margin | — | — | — | — | — | 1,021.9% | −252.4% | −174.0% | −236.0% | −341.7% | −257.2% | −273.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in WHWK's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
WHWK financial results
In fiscal year 2025 (ended December 31, 2025), Whitehawk Therapeutics reported revenue of $7.1 million, down 72.5% from the year before. It had a net loss of $20.6 million, a net profit margin of −288.3%. Diluted earnings per share came to −$1.71. Over five years revenue grew at an average rate of −13.3% a year.
See the WHWK stock overview for the latest quote and news, or the WHWK chart for price history and technical indicators.
WHWK income statement FAQ
What is Whitehawk Therapeutics's annual revenue?
Whitehawk Therapeutics reported total revenue of $7.1 million for fiscal year 2025, which ended on December 31, 2025. That was down 72.5% from $26.0 million the previous year.
Is Whitehawk Therapeutics profitable?
No. Whitehawk Therapeutics reported a net loss of $20.6 million in fiscal 2025, a net profit margin of −288.3%; its operating margin was −1,601.1%.
What is Whitehawk Therapeutics's gross margin?
Whitehawk Therapeutics's gross margin was 89.4% in fiscal 2025: for every $100 of revenue, Whitehawk Therapeutics kept $89 after the direct cost of its products and services.
How much does Whitehawk Therapeutics spend on research and development?
Whitehawk Therapeutics spent $91.0 million on research and development in fiscal 2025, 1,273.1% of revenue.
How fast is Whitehawk Therapeutics growing?
Revenue grew −13.3% a year on average over the last five fiscal years, from $14.6 million to $7.1 million.
What are Whitehawk Therapeutics's earnings per share?
Whitehawk Therapeutics earned $-1.71 per diluted share in fiscal 2025, compared with $-2.26 a year earlier.
When will Whitehawk Therapeutics report its next earnings?
Whitehawk Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Whitehawk Therapeutics's fiscal year end?
Whitehawk Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.